29.03.2013 • News

Arkema Clarification of Kem One Situation

The Lyon commercial court has decided to open insolvency proceedings with continuation of activities for a six-month observation period against the company Kem One, corresponding to the upstream part (chlorine / caustic soda electrolysis and PVC production) of the various businesses sold by Arkema to the Klesch Group.

Arkema points out that the divestment of the vinyl activities to the Klesch Group, finalized on July 2 2012, concerned a comprehensive industrial package coherent from an economic point of view, from upstream (chlorine / caustic soda electrolysis and PVC production) to downstream (PVC converting into compounds, pipes and profiles). Maintaining this integration was a key factor of Kem One's future success.

The Kem One group had a robust balance sheet at the time of the divestment (without any debt, a €100 million cash contribution, and many guarantees), and the Klesch Group made a commitment to develop a financing plan adapted to the needs of Kem One as from July 2012.

Arkema points out that the situation created today results from a unilateral act by the Klesch Group which has decided to split up the upstream (Kem One) and downstream (Kem One Innovative Vinyls) activities and not to put in place the contemplated funding and guarantees.

Arkema therefore expects that these insolvency proceedings will help clarify the reasons for the current situation (operation of the plants, management of the Lavra steamcracker force majeure event, evolution of margins and volumes), and trusts that they will also help ensure without delay that the financial resources made available to Kem One by Arkema have been used in accordance with their corporate purpose.

Arkema points out that the sale of the vinyl activities to the Klesch Group in July 2012 was completed in full transparency, in full regularity and in full compliance with the standard practices for this type of transactions, and is perfectly confident in its ability to demonstrate the same.

Finally, Arkema points out that its exposure to Kem One as at 31 December 2012, without any increase since, amounts to €125 million in total, corresponding to €65 million in receivables and €60 million in guarantees granted to third parties.

 

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read